Dr. Iris J. Lee, M.D.
Nephrology (Kidney) (Nephrology Physician)
- Medicare participating
At a glance
- Medical school
- Hahnemann University College of Medicine (1998)
- Years since graduation
- 28
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 113
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1998Medical school: Hahnemann University College of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Nephrology Physician primary
PA license MD073942L
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Temple University Hospital Philadelphia, PA
Medical groups
- Temple Faculty Practice Plan Inc (1,368 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 113
- Services billed
- 340
- Patients’ average age
- 62
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 79 | 34 |
| Established patient office or other outpatient visit, 40-54 minutes | 76 | 47 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 55 | 20 |
| Hemodialysis procedure with physician evaluation | 41 | 21 |
| Dialysis services, 4 or more physician visits per month (20 years or older) | 23 | 17 |
| Established patient office or other outpatient visit, 30-39 minutes | 20 | 16 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 20 | 20 |
| Hospital discharge day management, 30 minutes or less | 15 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Carvedilol Other prescribers in Philadelphia, PA | 33 |
| Chlorthalidone Other prescribers in Philadelphia, PA | 26 |
| Prednisone Other prescribers in Philadelphia, PA | 21 |
| Nifedipine Er (nifedipine) Other prescribers in Philadelphia, PA | 19 |
| Mycophenolate Mofetil Other prescribers in Philadelphia, PA | 14 |
| Hydroxychloroquine Sulfate Other prescribers in Philadelphia, PA | 12 |
| Mycophenolic Acid (mycophenolate sodium) | 12 |
| Losartan Potassium Other prescribers in Philadelphia, PA | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 8 companies reported 10 payments worth $2,433 in total to this clinician.
| Calliditas Therapeutics US Inc. | $2,254 |
|---|---|
| Veloxis Pharmaceuticals, Inc. | $39.96 |
| Ardelyx, Inc. | $33.38 |
| Novo Nordisk Inc | $24.35 |
| Travere Therapeutics, Inc. | $22.40 |
| Apellis Pharmaceuticals, Inc. | $20.36 |
| Takeda Pharmaceuticals U.S.A., Inc. | $19.63 |
| Amgen Inc. | $18.24 |
| Consulting Fee | $2,100 |
|---|---|
| Food and Beverage | $333 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Calliditas Therapeutics US Inc. Aug 21, 2025 | Consulting Fee TARPEYO · NEPHROLOGY | $2,100 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $12,369 in research payments for these studies, mostly to the institutions running them.
- LUPKYNIS Registry Study
Aurinia Pharma U.S., Inc. - An Adaptive, Randomized, Double-blind, Dose Exploration, Parallel Group, Placebo Controlled, Multicenter Phase 2 Trial to Evaluate the Efficacy, Safety and Tolerability of LNP023 in Combination With Standard-of-care W…
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.